[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356312-105":59,"doc-detail-356312-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-lysine-demethylase-kdm4c-is-an-oncogenic-driver-and-regulates-erk-activity-in-kras-mutant-pancreatic-ductal-adenocarcinoma","The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma","","Deregulation of chromatin regulators is widespread in pancreatic ductal adenocarcinoma (PDAC). Lysine demethylase 4C (KDM4C) is frequently overexpressed in solid tumors and linked to chromatin instability, proliferation, and stem-like features. KDM4C upregulation was observed in PDAC cell lines and patient samples. CRISPR/Cas9 deletion reduced growth and increased survival of orthotopic murine PDAC allografts, with transcriptomic and proteomic data implicating reduced activated phospho-ERK downstream of mutant RAS. Proximity labeling identified SIRT1 as a KDM4C Tudor-domain interactor, enabling DUSP2 repression and ERK dephosphorylation. Adaptive ERK signaling restoration occurred in KDM4C-null lines; the pan-KDM4 inhibitor TACH107 bypassed this adaptation and suppressed PDAC in vitro and in vivo. The findings support therapeutic targeting of KDM4C in KRAS-mutant PDAC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-lysine-demethylase-kdm4c-is-an-oncogenic-driver-and-regulates-erk-activity-in-kras-mutant-pancreatic-ductal-adenocarcinoma/356312/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-lysine-demethylase-kdm4c-is-an-oncogenic-driver-and-regulates-erk-activity-in-kras-mutant-pancreatic-ductal-adenocarcinoma/356312.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does KDM4C play in KRAS-mutant PDAC?","Question",{"text":112,"@type":113},"KDM4C is identified as an oncogenic driver that sustains ERK signaling in KRAS-mutant pancreatic ductal adenocarcinoma.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does deleting KDM4C affect PDAC growth and survival?",{"text":117,"@type":113},"CRISPR/Cas9-mediated KDM4C deletion reduces proliferation and clonogenicity and increases survival in orthotopically implanted murine PDAC allografts.",{"name":119,"@type":110,"acceptedAnswer":120},"Why does ERK signaling recover after long-term KDM4C loss, and how is it addressed?",{"text":121,"@type":113},"In vitro propagation of KDM4C-null PDAC lines leads to adaptation with restitution of ERK signaling; the pan-KDM4 inhibitor TACH107 bypasses this adaptive phenomenon and suppresses PDAC in vitro and in vivo.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356312,1790816854,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-25-0278](https://doi.org/10.1158/2767-9764.CRC-25-0278)  OPEN ACCESS  \nThe Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma  \nMenna-t-Allah Shaheen1,2, Sarah Dhebat1,2, Kimal I. Rajapakshe1,2, Bidyut Ghosh1,2,  \nBenson Chellakkan Selvanesan1,2, Shariq S. Ansari1,2, Cara L. Haymaker1, Dorsay Sadeghian3, Huamin Wang1,4, Ching-Fei Li5, Haoqiang Ying5, and Anirban Maitra1,2  \n􀀶  \nABSTRACT  \nDeregulation of proteins involved in chromatin regulation is common in pancreatic ductal adenocarcinoma (PDAC) . Lysine demethylase 4C (KDM4C) is one of the chromatin-modifying proteins frequently overexpressed across multiple solid cancers and is linked to chromatin instability, increased cell proliferation, and enhanced stem cell–like behavior. We observed upregulation of KDM4C protein in a panel of human PDAC cell lines and patient samples compared with nonneoplastic controls. CRISPR/Cas9-mediated deletion of KDM4C in human and murine PDAC cells reduced proliferation, clonogenicity, and increased survival of orthotopically implanted murine PDAC allografts. Transcriptomic and proteomic analyses revealed that loss of KDM4C in both human and murine PDAC cell lines was associated with the reduction of activated phospho-ERK, a pivotal effector downstream of mutant RAS. Using proximity labeling, we identified the histone deacetylase SIRT1 as a novel interacting protein with KDM4C via the latter’s Tudor reader domain. SIRT1-mediated deacetylation leads to repression  \nof downstream targets, including the dual specificity phosphatase DUSP2, which is known to inactivate ERK via dephosphorylation. In vitro propagation of KDM4C-null PDAC lines eventually led to adaptation and restitution of ERK signaling, with rescue of the KDM4C loss induced growth suppression. To bypass this adaptive phenomenon, we tested a preclinical pan-KDM4 inhibitor TACH107 and confirmed its efficacy in in vitro and in vivo PDAC models. Our studies identify KDM4C as an oncogenic molecule that sustains ERK signaling in KRAS-mutant PDAC and can be broadly targeted via small-molecule inhibitors.  \nSignificance: Our data suggests that KDM4C is a novel regulator of ERK signaling, the main effector pathway downstream of mutant RAS. This is the first demonstration linking the requirement of sustained KDM4 activity to ERK signaling in cancer and presents an opportunity to leverage this oncogenic pathway for therapeutic intervention.  \nIntroduction  \nPancreatic ductal adenocarcinoma (PDAC) is a highly recalcitrant neoplasmand is anticipated to become the second leading cause of cancer-related deaths in the United States by 2040 ( 1) . PDAC exhibits significant resistance  \n1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas. 4Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Current address for M. -t. -A. Shaheen and S.S. Ansari: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; current address for S. Dhebat, Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; current address for K. I. Rajapakshe and B. Chellakkan Selvanesan, Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer  \nto standard-of-care chemotherapeutic regimens, and despite extensive research efforts, the 5-year survival rate remains at a mere 12%(2) . Greater than 90% of PDAC harbor mutant KRAS, and alth","cbCailLr2Tt0uNvV","https://ap.wps.com/l/cbCailLr2Tt0uNvV","pdf",16334797,15,"English","# Abstract\n# Significance\n# Introduction","[{\"question\":\"What role does KDM4C play in KRAS-mutant PDAC?\",\"answer\":\"KDM4C is identified as an oncogenic driver that sustains ERK signaling in KRAS-mutant pancreatic ductal adenocarcinoma.\"},{\"question\":\"How does deleting KDM4C affect PDAC growth and survival?\",\"answer\":\"CRISPR/Cas9-mediated KDM4C deletion reduces proliferation and clonogenicity and increases survival in orthotopically implanted murine PDAC allografts.\"},{\"question\":\"Why does ERK signaling recover after long-term KDM4C loss, and how is it addressed?\",\"answer\":\"In vitro propagation of KDM4C-null PDAC lines leads to adaptation with restitution of ERK signaling; the pan-KDM4 inhibitor TACH107 bypasses this adaptive phenomenon and suppresses PDAC in vitro and in vivo.\"}]","The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma | PDF",1790124601,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fdb87481a784155fa9eb28e118ac60f0.webp",983,1263,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0fa18558b1870c382ff8e0648b9e1b4.webp",982,1262,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3855b537005d93c53a6a1d0f199579df.webp",981,1261,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/06a88ceb7aa1468f7aa4814870ac0837.webp",980,1259]